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Abstract: Osteoporosis is a complex multifactorial disorder of gradual bone loss and increased
fracture risk. While previous studies have shown the importance of many genetic factors
in determining peak bone mass and fragility fractures and in suggesting involvement of fibroblast
growth factor-2 (FGF-2) in bone metabolism and bone mass, the relationship of FGF-2 genetic
diversity with bone mass/osteoporosis has not yet been revealed. The current study investigated
the potential relevance of FGF-2 gene polymorphism in osteoporosis among a Zhuang ethnic Chinese
cohort of 623, including 237 normal bone mass controls, 227 osteopenia, and 159 osteoporosis of
different ages. Bone density was examined by calcaneus ultrasound attenuation measurement,
and single nucleotide polymorphisms (SNPs) and linkage disequilibrium analyses were performed
on five SNP loci of FGF-2 gene. Significant differences were found in bone mass in males between
the 45-year-old and ≥70-year-old groups (p < 0.01), and in females among 55, 60, 65 and 70-year-old
groups (p < 0.05). Males had higher bone mass values than females in the same age (over 55-year-old)
(p < 0.05). The proportions of individuals with normal bone mass decreased with age (65.2% to
40% in males, and 50% to 0% in females), whereas prevalence of osteoporosis increased with age
(15.4% to 30% in men, and 7.7% to 82% in women). Out of five FGF-2 SNP loci, the TA genotype of
rs308442 in the osteoporosis group (40.2%) was higher than in the control group (29.5%) (p < 0.05).
The TA genotype was significantly correlated with the risk of osteoporosis (odds ratio OR = 1.653),
95% confidence interval (CI): 1.968–1.441). Strong linkage disequilibrium in FGF-2 gene was also
detected between rs12644427 and rs3747676, between rs12644427 and rs3789138, and between
rs3747676 and rs3789138 (D’ > 0.8, and r2 > 0.33). Thus, the rs308442 locus of FGF-2 gene is closely
correlated to osteoporosis in this Zhuang ethnic Chinese cohort, and the TA may be the risk genotype
of osteoporosis.
Keywords: bone ultrasound; osteoporosis; human association studies; fibroblast growth
factor-2; aging
1. Introduction
Osteoporosis is a systemic skeletal disease characterized by a progressive reduction in bone mass
and deterioration of the bone architecture and strength, resulting in an elevated risk of fracture [1].
The incidence of osteoporosis is influenced by heredity, environment, gender, age, nutrition, life
style, physical exercise, drug use, disease, and various other factors. Among these factors, genetics
accounts for 60–85% of the influence [2]. Moreover, the occurrence of osteoporosis and osteoporotic
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fracture depends on peak bone mass obtained and bone loss rate, both of which are also influenced by
the aforementioned factors [3].
Previously, many genetic studies used the candidate gene approach to explore the genes associated
with osteoporosis [4–6]. For example, macrophage colony-stimulating factor, receptor activator of
nuclear factor-κB ligand, osteoprotegerin, interleukin-34, and other factors have been proven to
participate in the osteoclast differentiation through activation of the non-canonical Wnt pathway [4–6].
Also demonstrating a key role of the canonical Wnt pathway in determining bone mass, it was shown
that β-catenin deletion led to a decreased number of osteoblasts, an increased number of osteoclasts,
and decreased bone mass [7,8]. Furthermore, bone morphogenetic protein (BMP) signaling pathway
is also critical for cartilage and bone formation and postnatal bone development and regulation of
bone metabolism [9]. Due to their critical roles in regulating bone mass, these factors are either
currently and/or likely to be used as drug targets to intervene with the occurrence and development
of osteoporosis. However, further studies are required to identify other likely genetic factors
for osteoporosis.
Fibroblast growth factor (FGF-2) is a growth factor produced by and released from
epithelial and mesenchymal cells. FGF-2 can regulate normal cell division, proliferation, migration,
and differentiation [10]. Moreover, FGF/FGF receptor (FGFR) signaling has been found to
be an important pathway in skeletal development [11]. Lei et al. [12] showed that FGF-2 can
promote osteogenic differentiation of cultured human bone marrow mesenchymal stem cells.
Naganawa et al. [13] exhibited that bone formation in FGF-2 gene knockout mouse was obviously
decreased. Nagayasu-Tanaka et al. [14] proved the role of FGF-2 in bone formation and osseointegration.
While evidence above confirmed that FGF-2 plays an important role in bone formation and bone mass
determination, the relationships between FGF-2 genetic diversity with bone mineral density (BMD) and
with risk of osteoporosis have not yet been revealed.
Since FGF-2 is known to be important in regulating skeletal development and formation of
osteoblasts [15], and previously, Hao et al. [16] observed relationships of plasma FGF-2 levels
and polymorphism of FGF-2 gene with the obese phenotype of the Chinese Han population,
in the current study, we speculated that FGF-2 gene polymorphism and its haplotypes may be related to
the occurrence and development of osteoporosis. To determine whether FGF-2 can be used as a genetic
marker to predict the risk of osteoporosis in middle-aged and elderly people, the relationship between
FGF-2 haplotypes and bone mass was explored, and the distribution of FGF-2 gene polymorphism and
its haplotypes in osteoporosis patients and normal bone mass people were analyzed in middle-aged
and senior Zhuang ethnic people in Guangxi, a multi-ethnic region of China.
2. Results
2.1. The Bone Mass Decreasing Trends of the Male and Female Groups with Age
Data for the measured broadband ultrasound attenuation (BUA) showed a gradual declining
trend of bone mass with increasing age. The trends of changes in bone mass in senior and middle-aged
Zhuang men and women in Guangxi are shown in Table 1 and Figure 1. A significant difference
was found in the male BUA between the 45-year-old and ≥70-year-old groups (p < 0.01), but no
statistical differences were found among the 50, 55, 60, and 65-year-old groups (p > 0.05). Similarly,
BUA values of women gradually decreased with age. Significant differences were found in the BUA
values between the ≥70-year-old group and the other age groups (p < 0.01). Additionally, significant
differences were found between the male and female groups, respectively, for the 55, 60, 65, and
70-year-old groups (p < 0.01). However, for the 45 and 50-year-old groups, males and females had
the similar BUA values.
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Table 1. Bone mass measurement results as broadband ultrasound attenuation (BUA).
Age Groups BUA (g/cm2)
n Males n Females
45 26 60.03 ± 5.99 14 59.62 ± 5.47
50 66 62.74 ± 4.59 78 61.63 ± 5.44
55 59 61.81 ± 5.52 83 58.02 ± 4.07 **
60 81 60.67 ± 4.66 69 56.62 ± 4.77 **
65 59 59.94 ± 6.01 67 54.69 ± 4.16 **
70 10 58.79 ± 5.17 11 52.58 ± 2.03 **
Total 301 61.09 ± 5.32 322 57.79 ± 5.29 **
Data as x ± SD; ** p < 0.01 versus males.
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old group, the proportion gradually decreased from 50.9% to 40%. The relatively small sample size 
of the 45-year-old group may have led to the higher percentage of individuals with normal bone mass 
in the 50-year-old group than the 45-year-old group. 
The proportion for females with normal bone mass in the 45-year-old group was 42.7%, which 
increased to 50% in the 50-year-old group. It then decreased from 21.7% in the 55-year-old group to 
0% in the 70-year-old group. Again, the relatively small sample size of the 45-year-old group may 
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Figure 1. Changes in the bone mass density (assessed as broadband ultrasound attenuation or BUA)
with age of senior and middle-aged Zhuang people in Guangxi (** p < 0.01 versus males).
Trends of percentage changes in individuals with normal bone mass, osteopenia, and osteoporosis
among the senior and middle-aged Zhuang people in Guangxi are shown respectively in Figures 2–4.
The age-related changes in numbers and prevalence of individuals with normal bone mass, osteopenia,
and osteoporosis are shown in Table 2. As shown in Figure 2, the number and proportion of
Zhuang people with normal bone mass gradually decreased as age increased for both men and
women. The proportion of males with normal bone mass in the 45-year-old group was 46.2%,
which then increased to 65.2% in the 50-year-old group. From the 55-year-old group to the 70-year-old
group, the proportion gradually decreased from 50.9% to 40%. The relatively small sample size of
the 45-year-old group may have led to the higher percentage of individuals with normal bone mass
in the 50-year-old group than the 45-year-old group.
The proportion for females with normal bone mass in the 45-year-old group was 42.7%,
which increased to 50% in the 50-year-old group. It then decreased from 21.7% in the 55-year-old
group to 0% in the 70-year-old group. Again, the relatively small sample size of the 45-year-old group
may have led to the lower percentage of individuals with normal bone mass than the 50-year-old group
(Figure 2).
In contrast, the number and proportion of Zhuang people with osteopenia and osteoporosis
gradually increased. Proportions of osteopenia fluctuated from 28.8% (in the 50-year-old group)
to 40.7% (in the 55-year-old group) in males, and from 53.0% (in the 55-year-old group) to 18.2%
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(in the 70-year-old group) in females (Figure 3). Prevalence of osteoporosis in Zhuang men increased
with age from 15.38% (in the 45-year-old group) to 30% (in the 70-year-old group) (p < 0.01), whereas
that in Zhuang women increased from 7.69% (in the 50-year-old group) to 81.81% (in the 70-year-old
group). Furthermore, while no strict changes in proportions of normal bone mass, osteopenia,
or osteoporosis were found between adjacent age groups, the tendency was roughly consistent with
the change of age for all groups (Figure 4) (p < 0.01) (Table 2).
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Figure 4. Trends of percentage changes with age in individuals with osteoporosis among senior and
middle-aged Zhuang people (** p < 0.01 versus males, *** p < 0.001 versus males).
Table 2. The age-related changes in numbers and prevalence of individuals with normal bone mass,
osteopenia, and osteoporosis.
Age Groups Normal (n, %) Osteopenia (n, %) Osteoporosis (n, %)
Male Female Male Female Male Female
45 12, 46.15% 6, 42.86% 10, 38.46% 5, 35.71% 4, 15.38% 3, 21.43%
50 43, 65.15% 39, 50% 19, 28.79% 33, 42.31% 4, 6.06% 6, 7.69%
55 30, 50.85% 18, 21.69% 24, 40.68% 44, 53.01% 5, 8.47% 21, 25.3%
60 41, 50.62% 15, 21.74% 28, 34.57% 22, 31.88% 12,14.81% 32, 46.38%
65 24, 40.68% 5, 7.46% 18, 30.51% 19, 28.36% 17, 28.81% 43, 64.18%
≥70 4, 40% 0, 0% 3, 30% 2, 18.18% 3, 30% 9, 81.82%
Total 154, 51.16% 83, 25.78% 102, 33.89% 125, 38.82% 45, 14.95% 114, 35.4%
χ2 = 144.653, p = 0.000.
2.2. FGF-2 Genotype and Allelic Gene Frequency Distribution
The detection of five SNP loci of FGF-2 gene shows the polymorphism of five polymorphic loci
of FGF-2 gene existing in the Zhuang people of Guangxi, China. The distributions of genotypes
and allelic gene for all polymorphic loci of the FGF-2 gene are shown in Table 3. The five
polymorphic loci (rs308379, rsl2644427, rs3789138, rs308442, and rs3747676) of the FGF-2 gene reached
the Hardy-Weinberg equilibrium through χ2-test (p > 0.05). The distribution frequency of the TA
genotype in the rs308442 of the FGF-2 gene in the normal group (50 cases) was significantly lower
than that in the Osteopenia group (84 cases) or that in Osteoporosis group (91 cases) (p < 0.05).
Furthermore, the TA genotype of rs308442 was significantly correlated with the risk of osteoporosis
(Normal vs. Osteoporosis: odds ratio, OR = 1.652, 95% confidence interval, CI: 1.960–1.424, p = 0.031;
Normal vs. Osteopenia: OR = 1.653, 95% CI: 1.968–1.441, p = 0.033). No statistically significant
differences were found in the distributions of genotypes and allelic gene of the remaining four
polymorphic loci of FGF2 gene (rs308379, rsl2644427, rs3789138, and rs3747676) (p > 0.05) (Table 3).
The bone mass density of TA genotype (58.75 ± 5.45) in the rs308442 of the FGF-2 gene was lower
than that of TT (61.04 ± 5.81) or AA (60.59 ± 5.55) genotype (p < 0.05). However, no statistically
significant differences were found within genotypes in the other four FGF-2 SNP loci (rs308379,
rsl2644427, rs3789138, and rs3747676) (p > 0.05) (Table 4).
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Table 3. Comparisons of distributions of genotype frequency in the five single nucleotide
polymorphism (SNP) loci of FGF-2 among the Normal, Osteopenia, and Osteoporosis groups.
Normal vs. Osteoporosis Normal vs. Osteopenia
Loci Genotype Normal Osteopenia Osteoporosis OR (95% CI) p OR (95% CI) p
rs12644427 AA 65 59 41 1.000 1.000
GA 111 110 81 0.864 (1.403–0.532) 0.555 0.916 (1.422–0.590) 0.696
GG 61 58 37 1.040 (1.832–0.591) 0.892 0.955 (1.579–0.577) 0.857
Allelic gene
A 241 228 163 1.000 1.000
G 233 226 155 1.017 (1.351–0.765) 0.909 0.975 (1.262–0.754) 0.849
rs308379 TT 82 84 43 1.000 1.000
TA 109 101 82 0.697 (1.112–0.437) 0.129 1.106 (1.661–0.736) 0.629
AA 46 42 34 0.709 (1.263–0.399) 0.243 1.122 (1.882–0.669) 0.663
Allelic gene
T 273 269 168 1.000 1.000
A 201 185 150 0.825 (1.097–0.62) 0.186 1.071 (1.39–0.824) 0.609
rs308442 TT 146 124 87 1.000
TA 50 84 91 1.652 (1.960–1.424) 0.031 1.653 (1.968–1.441) 0.033
AA 21 12 8 1.565 (3.690–0.664) 0.303 1.486 (3.142–0.703) 0.297
Allelic gene
T 362 339 238 1.000 1.000
A 112 115 80 0.92 (1.281–0.662) 0.623 0.912 (1.23–0.676) 0.547
rs3747676 TT 69 70 43 1.000 1.000
CT 112 103 85 0.821 (1.319–0.511) 0.415 1.103 (1.690–0.720) 0.652
CC 56 54 31 1.126 (2.012–0.630) 0.689 1.052 (1.735–0.638) 0.842
Allelic gene
T 250 243 171 1.000 1.000
C 224 211 147 1.042 (1.386–0.784) 0.776 1.032 (1.336–0.797) 0.811
rs3789138 AA 71 70 43 1.000 1.000
GA 116 104 87 0.808 (1.292–0.505) 0.372 1.100 (1.679–0.720) 0.660
GG 50 53 29 1.044 (1.89–0.577) 0.887 0.930 (1.546–0.560) 0.780
Allelic gene
A 258 244 173 1.000 1.000
G 216 210 145 0.999 (1.329–0.751) 0.994 0.973 (1.259–0.751) 0.834
Table 4. Comparisons of bone mass density in the five SNP loci of FGF-2 among normal bone mass
(Normal), Osteopenia, and Osteoporosis groups.
Loci Genotype Normal Osteopenia Osteoporosis Total
rs12644427 AA 64.88 ± 3.84 58.11 ± 1.52 52.85 ± 1.53 59.47 ± 5.51
GA 65.39 ± 3.52 58.18 ± 1.55 52.67 ± 2.00 59.35 ± 5.69
GG 64.83 ± 2.97 57.93 ± 1.4 52.51 ± 1.87 59.34 ± 5.36
p 0.505 0.585 0.791 0.791
rs308379 TT 65.02 ± 3.55 58.03 ± 1.48 52.82 ± 2.28 59.17 ± 5.36
TA 65.29 ± 3.58 58.16 ± 1.53 52.52 ± 1.7 59.24 ± 5.76
AA 64.82 ± 3.12 58.08 ± 1.49 52.88 ± 1.62 59.70 ± 5.37
p 0.715 0.846 0.545 0.593
rs308442 TT 64.96 ± 3.45 58.11 ± 1.48 52.68 ± 1.98 61.04 ± 5.81
TA 65.24 ± 3.62 58.03 ± 1.52 52.67 ± 1.72 58.75 ± 5.45
AA 65.68 ± 3.25 58.48 ± 1.65 52.69 ± 1.62 60.59 ± 5.55
p 0.624 0.630 1.000 0.03
rs3747676 TT 64.83 ± 2.85 57.82 ± 1.44 52.51 ± 1.85 59.67 ± 5.05
CT 65.57 ± 3.76 58.16 ± 1.52 52.57 ± 1.98 59.34 ± 5.93
CC 64.53 ± 3.53 58.34 ± 1.52 53.22 ± 1.4 59.22 ± 5.30
p 0.140 0.137 0.191 0.757
rs3789138 AA 64.73 ± 2.87 57.83 ± 1.44 52.51 ± 1.85 59.25 ± 5.27
GA 65.54 ± 3.7 58.16 ± 1.52 52.6 ± 1.97 59.38 ± 5.91
GG 64.64 ± 3.65 58.32 ± 1.53 53.15 ± 1.42 59.58 ± 5.09
p 0.167 0.161 0.301 0.873
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2.3. Linkage Disequilibrium (LD) Analyses
Haploview 4.2 free software (from http://www.broadinstitute.org/haploview/haploview-
downloads) was used to simulate LD for the five SNP loci of the detected FGF-2 gene. LD coefficients
D’ and r2 between FGF-2 mutant loci are shown in Tables 5 and 6, respectively. The results showed
the LD coefficients of D’ > 0.8 and r2 > 0.33 between rs12644427 and rs3747676, between rs12644427
and rs3789138, and between rs3747676 and rs3789138 of FGF-2 gene. These results indicate a strong
LD. The LD coefficient between the remaining two loci did not meet the Hardy-Weinberg equilibrium,
which indicates a lack of strong LD (D’ < 0.8 or r2 < 0.33). The LD types between the case and control
groups were almost the same.
Table 5. Linkage disequilibrium (LD) coefficient D’ in FGF-2 mutant loci.







rs12644427 0.144/0.162 0.553/0.524 0.922/0.875 0.966/0.811
rs308379 0.124/0.107 0.182/0.210 0.183/0.174
rs308442 0.238/0.291 0.230/0.214
rs3747676 0.997/0.895
Table 6. Linkage disequilibrium (LD) coefficient r2 in FGF-2 mutant loci.
Mutant loci rs308379 rs308442 rs3747676 rs3789138
rs12644427 0.016 0.097 0.725 0.767
rs308379 0.007 0.022 0.021
rs308442 0.021 0.020
rs3747676 0.959
FGF-2 gene LD and haplotype block structure are shown in Figure 5 with values in the cells
indicating the genetic linkage logarithm of odds (LOD) score of D’. These results show that five SNPs
of FGF-2 gene are in incomplete linkage disequilibrium, and there is no haplotype is constituted
(Tables 5 and 6).Int. J. Mol. 2017, 18, 1358 8 of 14 
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3. Discussion
It is now believed that 50–85% of the variance in BMD and risks of osteoporosis is controlled by
genetic factors which are mostly polygenic [2]. Guangxi of China is a multi-ethnic region, and the study
on gene polymorphism of its population is very important to explore the distribution characteristics of
pathogenic and susceptibility genes of osteoporosis and to study osteoporosis on the pathogenesis
and gene levels. In this study, the trends of age-related changes of bone mass (as estimated by
calcaneus ultrasound attenuation) were analyzed among senior and middle-aged Zhuang ethnic
people in Guangxi. In addition, differences in the FGF-2 gene polymorphism in five SNP loci
between osteoporosis patients and individuals with normal bone mass were assessed, and the linkage
disequilibrium (LD) of FGF-2 in the five SNP loci was evaluated. The current study has shown a clear
relationship between FGF-2 gene polymorphism and bone mass, and by investigating SNPs and
haplotype of FGF-2 gene and the risk of osteoporosis, FGF-2 gene was shown to be potentially useful
genetic marker for predicting osteoporosis risk in senior and middle-aged Zhuang people.
3.1. Age-Related Changing Trends of Bone Mass
Calcaneus quantitative ultrasound measurement has become an internationally recognized method
for bone health examination and osteoporosis/fracture risk prediction. This process is noninvasive,
nonradioactive, easy to operate, low cost, and precise. Calcaneus quantitative ultrasound measurement
can be used to fully reflect bone mass, bone structure, and bone properties, because almost all cancellous
substances are sensitive to changes in bone mass. Moreover, several studies have proved that calcaneus
ultrasound parameters can sensitively reflect the changes in bone mineral and collagen contents [17].
Calcaneus ultrasound can be used as an effective tool for bone health survey [18] and prediction of
fracture risk of senior and middle-aged people [19]. In this study, bone mass was measured using
calcaneus quantitative ultrasound, which can objectively reflect the trends of changes in population
bone density with age.
The effect of aging on BMD is irreversible [20]. Adammi et al. studied the relationship between
bone density with age, body weight, and life style and found a significant negative correlation between
bone and age [21]. Evans also verified that the bone density in normal weight and obese population
decreased with age [22]. In the current study, bone density in the senior and middle-aged Zhuang
people in Guangxi showed a gradual decline with age. While the decline in males was found to
be smooth and gradual, significant bone mass differences were found only between the ≥70-year-old
group and 45-year-old group, although the differences among the other age groups of males were not
significant. Thus, the bone mass of this male population started to significantly decrease from 70 years
old, and this age group would later have a low bone density. This phenomenon is believed to be due
to the fact that local males maintain long outdoor labor time until the senior age, as they are the major
labor force of the family.
The decreases in BMD in the senior and middle-aged Zhuang females were found to be larger
and to occur faster. In particular, bone density of the ≥50-year-old females decreased sharply.
The proportions of individuals with normal bone mass decreased from 50% for the 50-year-old
group to 0% for the 70-year-old group, while proportions of osteoporosis increased correspondingly
from 7.69% to 81.82%. This sharp decrease in bone mass is believed to be due to the fact that most
females aged 55 have been in menopause, which is characterized with a sudden decrease in estrogen
secretion. Following menopause, bone resorption rate is known to be greater than bone formation rate,
and bone loss becomes considerable, reaching 2.0–3.0% annually, compared to the annual bone loss
caused by aging being approximately 1.0% (present in both males and females) [23]. After 70 years
of age, the decrease in bone density was more evidently affected by the estrogen deficiency and
aging. Male bone density, on the other hand, gradually decreased with age, and its declining trend
was smoother and slower than that of females. Donner et al. [24] investigated the impact of androgenic
hormone on bone density using rats and showed that age-related testosterone deficiency can cause
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femoral osteoporosis of experimental animals, as well as adverse bone geometry and impaired bone
strength in male rats. These conclusions are consistent with the results obtained in the present study.
3.2. Distribution of FGF-2 Gene SNPs in Zhuang Osteoporosis Patients and Normal Bone Mass Individuals
Since the cellular growth factor FGF-2 is known to be important in skeletal development and
metabolism due to its effects in chemotaxis, mitosis, in the formation of chondrocytes and osteoblasts,
and in angiogenesis [16,25–28], in the current study, we speculated that FGF-2 gene polymorphism
and its haplotypes may be related to the occurrence of osteoporosis. The FGF gene is located
at the 4q26-4q27 chromosome, which is composed of 71.529 kb base, including three exons and
two introns. At present, 8253 SNPs of FGF-2 have been verified according to the NCBI database
(https://www.ncbi.nlm.nih.gov/). FGF-2 gene polymorphism has been proved to be significantly
associated with the occurrence of various diseases or cancers. Hao et al. [16] observed relationships
of plasma FGF-2 levels and polymorphism of FGF-2 gene with the obese phenotype of Chinese Han
population. Wang et al. [29] found that one SNP locus rs11737764 of the FGF-2 gene is significantly
associated with the increase of osteosarcoma susceptibility. Kang et al. found that FGF-2 754C/G
polymorphic loci are significantly associated with the occurrence of ectopic endometrium, and people
with G allelic gene have a low risk of the disease [30]. Slattery et al. demonstrated that the combined
action of FGF-2 gene polymorphic loci and growth factor pathway-related genes can affect the risk of
breast cancer [31]. Some studies have reported that FGF-2 gene SNPs, namely, rs6854081, rs1048201,
and rs7683093, are significantly associated with bone density of collumfemoris. Moreover, three SNP
loci (rs6854081, rs1048201, and rs7683093) of FGF-2 gene have been proved to be closely related to
the bone mass density of the femur neck [32]. The increase of expression in FGF-2 in the bone has
been suggested to promote the occurrence and development of osteoporosis and is associated with
pathogenesis of osteoporosis [11].
Analyses of the distributions of five SNPs of the FGF-2 gene and its genotype in Zhuang
osteoporosis patients and normal bone mass individuals showed that five SNPs of the FGF-2 gene,
namely, rs308379, rsl2644427, rs3789138, rs308442, and rs3747676, reached Hardy-Weinberg equilibrium
by χ2-test (p > 0.05). This result indicates that the distributions of various groups of genotypes of
many loci of FGF-2 gene in the studied populations have reached genetic equilibrium. Among the five
SNPs of the FGF-2 gene, the distribution frequency of the only mutant genotype TA in rs308442 locus
in the case group (40.2%) was higher than that in the control group (29.5%). Our data suggests that TA
is a risk factor of osteoporosis (OR = 1.531, 95% CI: 2.179–1.078) (Table 3). The differences in genotype
frequency and allelic gene frequency of the remaining four loci of FGF-2 gene, namely, rs308379,
rsl2644427, rs3789138, and rs3747676, between the case and control groups showed no statistical
significances (p > 0.05).
The results are consistent with the study of Dong et al. on the correlation between the bone
density of collumfemoris and FGFR-2 gene polymorphism in the Han population [33]. They showed
that two of the 28 SNPs of the FGFR-2 gene (i.e., rs11200014 and rs1078806) are significantly associated
with bone density of collumfemoris. Furthermore, analyses showed that FGF-2 and its receptor FGFR-2
are similarly associated with bone density. Thus, based on these previous studies and our current data,
FGF-2 signal pathway participates in the occurrence and development of osteoporosis.
3.3. Linkage Disequilibrium (LD) Analyses of the SNPs of FGF-2 Gene
D’ and r2 are two common parameters for assessing LD. The probability of the occurrence of
recombination events in the LD area can be directly reflected with the value of D’, and the validity of
association analysis is directly related to r2. Several studies have suggested that if |D’| > 0.8, then two
loci are in strong LD. If r2 > 0.33, two SNPs are closely linked to be inherited as a whole [34,35].
However, D’ is relatively insensitive to the changes in gene frequency, and when a gene frequency
in a locus is lower, r2 is more reliable than D’ [36].
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In this study, to determine the association of FGF-2 SNPs with osteoporosis, LD analyses
were performed by pairs of the five polymorphic loci of FGF-2, and D’ and r2 were comprehensively
analyzed. Strong LDs were shown between rs12644427 and loci rs3747676 and rs3789138, and between
rs3747676 and rs3789138 (D’ > 0.8 and r2 > 0.33). These results indicate the likely linkage units among
three SNP loci, namely, rs12644427, rs3747676, and rs3789138. However, no correlation was found
between the polymorphism of rs12644427, rs3747676, rs3789138, and osteoporosis, and locus rs308442
(which is associated with osteoporosis) has no linkage relation with the loci rs1264427, rs3747676,
and rs3789138. Thus, these three SNP loci do not likely participate in the occurrence and development
of osteoporosis. Moreover, rs308442 locus do not react with the other loci. Furthermore, LD types by
pairs among the most loci in the case and control groups were basically similar.
The degree of LD between loci is not necessarily related to the distance between the loci. Of the two
groups of the population, no haplotype block was found. Therefore, the relationship between FGF-2
polymorphism and osteoporosis cannot be judged through LD analysis results.
4. Materials and Methods
4.1. Analyses of Bone Density
Firstly, a standard height measuring instrument (HF50, Hengfeng, Chengde, China) was used to
measure the net height of subjects. A biological electrical impedance analyzer (MC-180, Tanita, Japan)
was used to determine body composition which recorded net body mass, body mass index, and other
pertinent data. Achilles Express (GE, Fairfield, IA, USA) was used to perform broadband ultrasound
attenuation (BUA) of the right calcaneus of subjects. Prior to ultrasonic BMD detection, 100 samples
were chosen randomly, and their BMDs were measured both by applying the dual-energy X-ray
absorptiometry (DXA) and quantitative ultrasound methods. After comparison tests, a calibration
formula was established, from which a standard module was used for the calibration to ensure
the accuracy of the results from the ultrasound method. Bone mass results are represented with BUA,
which was based on T-score in decibels per megahertz.
4.2. Analyses of FGF-2 Gene Polymorphism
Venous blood (3mL) was extracted from each of the 623 volunteers. After anticoagulation with
ethylenediaminetetraacetic acid (EDTA) and conventional proteinase K digestion, the genomic DNA
in the white blood cells was extracted using phenol-chloroform method [37], and the DNA sample
was stored at−20◦C. Prior to use, 1% agarose gel electrophoresis was performed to assess DNA quality
and concentration, and DNA samples were diluted to the working concentration of 5–10 ng/µL.
We searched the chromosome location and gene sequence of FGF-2 gene in the NCBI database
and single nucleotide polymorphism (SNP) loci selected in the SNP database. Based on NCBI database,
we further searched information about FGF-2 genetic variation from the International Hap-Map Project
database (https://www.genome.gov/10001688/). Haploview 4.2 software was employed to determine
the distribution frequency of polymorphic loci. The Tagger function was used to select SNPs with
properties of r2 > 0.8 and minor allele frequency (MAF) > 0.05. As a result, rs308379, rs12644427,
rs3789138, and rs308442 loci of the first intron of FGF-2 gene and rs3747676 locus of the third exon
of the 3′-UTR were selected for analyses for the current study. Primer 5 software was used to design
primers, which were synthesized by GENESKY (Shanghai Genesky Biotech Co., Ltd., Shanghai, China).
The related information on primers is shown in Table 7.
The gene amplification was carried out in PCR reactions of 20 µL, which included 2 µL of
10×buffer, 2.2 µL of MgCl2 (25 mmol/L), 0.8 µL of dNTPs (10 mmol/L), 1 µL for each upstream and
downstream primers (10 µmol/L), 1 µL of template, 0.2 µL of Taq DNA polymerase, and an appropriate
amount of double-distilled water to obtain 20 µL volume. PCR reaction conditions were as follows:
95 ◦C for 2 min; 11 cycles of 94 ◦C for 20 s, 65–0.5 ◦C/cycle for 40 s, and 72 ◦C for 1.5 min; 24 cycles
of 94 ◦C for 20 s, 59 ◦C for 30 s, and 72 ◦C for 1.5 min; 72 ◦C for 2 min; and 4 ◦C.PCR products
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were firstly purified with shrimp alkaline phosphatase (SAP, Promega, Madison, WI, USA) and
Exonuclease I (EXO I, Epicentre, Wisconsin, USA) and then were used for the extension reaction
with SNaPshot Multiplex kit (Applied Biosystems, Foster, CA, USA). The conditions for extension
reaction were as follows: 96 ◦C for 1 min; 28 cycles of 96 ◦C for 10 s, 50 ◦C for 5 s, and 60 ◦C for 30 s;
and 4 ◦C. The extension product after purification by SAP was sampled on ABI3130xl. SNP genotyping
was analyzed with GeneMapper 4.0 (Applied Biosystems).
Table 7. PCR primers for the five single nucleotide polymorphisms (SNPs) of the FGF-2 gene.


























4.3. Linkage Disequilibrium (LD) Analyses on the Five SNP Loci of FGF-2 Gene
SNPs on the same chromosome are not isolated, and SNPs of adjacent allelic genes tend to appear
simultaneously. In this study, to analyze the LD of the five SNP loci of the FGF-2 gene, Haploview 4.2
software was used to detect their D’ and r2 vales.
4.4. Statistical Analyses
Data was represented as x ± SD. The enumeration data was tested using χ2-test. Fitting χ2
was used to detect whether the gene frequency satisfied the Hardy-Weinberg equilibrium law.
PHASE 1.0 software (free software from: http://www.stat.washington.edu/stephens/home.html)
was used to construct haploids. Odds ratio (OR) values and 95% confidence interval (CI) were used
to measure the correlation between polymorphism of FGF-2 gene and osteoporosis susceptibility.
All statistical tests were two-sided probability tests. Sample size was determined using online
calculating tools (www.powerandsamplesize.com/Calculators/). p Values less than 0.05 indicated
statistical significance. SPSS 18.0 software (IBM, Beijing, China) was used for the statistical analyses.
5. Conclusions
The current study has shown age-related gradual declines in males and fast and large decreases
in females in the calcaneal ultrasound BMD in the senior and middle-aged Zhuang people in Guangxi,
China. By analyzing distributions of FGF-2 gene polymorphism and by exploring correlations between
five SNPs of FGF-2 gene and the BMD in osteoporosis patients and in senior and middle-aged normal
bone mass controls, the current study demonstrated that rs308442 locus of FGF-2 gene is closely
correlated to osteoporosis and that the TA may be the risk genotype of osteoporosis. Further studies,
such as measurements of serum FGF-2 levels and bone FGF-2 mRNA and protein expression levels
in both osteoporosis patients and age-matched normal bone mass individuals, are required to prove
whether FGF-2 gene may potentially useful as a genetic marker to predict the risk of osteoporosis
in senior and middle-aged Zhuang people.
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